Gilead's PURPOSE 5 study shows higher persistence among patients starting twice-yearly lenacapavir for HIV prevention

Gilead Sciences announced results from its PURPOSE 5 study demonstrating higher persistence among patients starting twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis.

Detected & updated continuously · Source: Nebula